MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
17.26
+0.40
+2.37%
After Hours: 17.01 -0.25 -1.47% 19:52 12/04 EST
OPEN
16.84
PREV CLOSE
16.86
HIGH
17.63
LOW
16.57
VOLUME
659.17K
TURNOVER
--
52 WEEK HIGH
17.63
52 WEEK LOW
3.500
MARKET CAP
1.12B
P/E (TTM)
68.90
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks · 1d ago
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Simply Wall St · 1d ago
Weekly Report: what happened at GLUE last week (1124-1128)?
Weekly Report · 3d ago
Monte Rosa: Looking Mispriced After Big Pharma Validation
Seeking Alpha · 5d ago
Weekly Report: what happened at GLUE last week (1117-1121)?
Weekly Report · 11/24 10:41
Weekly Report: what happened at GLUE last week (1110-1114)?
Weekly Report · 11/17 10:42
Weekly Report: what happened at GLUE last week (1103-1107)?
Weekly Report · 11/10 10:39
Reported Saturday, Monte Rosa Therapeutics Presents Preclinical Data At AHA 2025 Demonstrating MRT-8102 NEK7-Directed Molecular Glue Degrader Modulates NLRP3 Inflammasome In Cardiovascular And Cardiometabolic Diseases
Benzinga · 11/10 09:03
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.